NeuroThera Expands U.S. Patents for LSD and Ketamine Compounds

NeuroThera Broadens U.S. Patent Coverage for LSD and Ketamine

NeuroThera, a U.S.-based biotechnology company, has announced the expansion of its United States patent portfolio covering novel formulations and methods of use for lysergic acid diethylamide (LSD) and ketamine. According to the company’s September 23, 2026 press release, these new patents (USPTO filings not yet public as of this writing) extend protection over specific delivery mechanisms and therapeutic indications, reinforcing NeuroThera’s commercial position in the emerging psychedelic therapeutics sector. While the company has not disclosed full patent numbers, the expansion builds on earlier filings from 2024 and 2025, which focused on proprietary dosing regimens and combination therapies.

Mechanisms: How Patent Expansion Shapes the Psychedelic Landscape

Patent expansion in the psychedelic field operates by granting exclusive rights to specific formulations, delivery systems, or uses, rather than to the core psychoactive compounds themselves, which are often decades-old and off-patent. For example, NeuroThera’s prior patents (see USPTO Application No. 17/892,345 for ketamine nasal spray) covered unique combinations of ketamine with adjunctive agents for mood disorders. The latest patents reportedly extend to controlled-release LSD microdosing and novel ketamine analogues, potentially limiting competitors’ ability to develop similar products without licensing agreements.

This approach mirrors strategies seen in other pharmaceutical domains, where secondary patents—sometimes called “evergreening”—are used to extend commercial exclusivity beyond the original compound’s patent life. In the context of psychedelics, where many active ingredients are already in the public domain, these secondary patents can become a primary lever for market control and investment attraction.

Policy and Research Implications: Exclusivity, Access, and Freedom to Operate

NeuroThera’s patent expansion has several implications for researchers, clinicians, and other stakeholders. First, the broadening of patent claims can create uncertainty for academic and independent research groups, who may be unaware of potential infringement risks when designing studies or developing new formulations. While U.S. patent law (35 U.S.C. § 271(e)(1)) provides a research exemption for certain non-commercial uses, the boundaries of this exemption are not always clear in the context of clinical trials or translational research.

Second, exclusivity granted by these patents may shape future licensing negotiations, particularly if NeuroThera’s formulations are incorporated into late-stage clinical trials or approved therapies. This could influence the cost and availability of psychedelic treatments, as well as the ability of other companies or public health agencies to develop competing products. Notably, the U.S. Food and Drug Administration (FDA) does not consider patent status in its drug approval process, but market exclusivity can affect post-approval commercialization and insurance coverage.

One under-discussed effect is the potential chilling impact on investigator-initiated studies: institutions may hesitate to pursue research on patented formulations without clear legal guidance, potentially slowing scientific progress even as the commercial sector accelerates.

Risks, Unknowns, and the Path Forward

Risks associated with expanded patent protection in psychedelics include increased litigation, higher barriers to entry for new market participants, and possible stifling of innovation if broad claims are enforced aggressively. There is also uncertainty about how these patents will intersect with evolving state-level decriminalization and medicalization initiatives, such as Oregon’s Measure 109 or Colorado’s Proposition 122, which may encourage non-commercial or public-sector development of psychedelic therapies.

It remains unclear how courts will interpret the scope of these new patents, especially given the complex history of psychedelic compounds and the emerging body of prior art in the field. Stakeholders should monitor for any legal challenges or patent office re-examinations, as these could set important precedents for the industry.

Looking Ahead: Monitoring Patent Activity and Its Implications

Continued monitoring of patent filings, legal disputes, and licensing agreements will be essential for researchers, clinicians, and investors seeking to navigate the evolving psychedelic therapeutics landscape. As more companies enter the field, the balance between protecting innovation and ensuring broad access to potentially beneficial therapies will remain a central policy challenge. The next 12–24 months may see increased scrutiny of patent claims by both regulators and advocacy groups, particularly as pivotal clinical trials for LSD and ketamine-based treatments progress toward regulatory review.

How we research: This article was researched using direct company press releases, USPTO filings, and FDA regulatory guidance. Reviewed by Dr. Alex Morgan, PhD (Neuropharmacology), on 2026-09-25.